血栓性微血管病：多聚体、金属蛋白酶及其他。
Thrombotic microangiopathies: multimers, metalloprotease, and beyond.
机构信息
Rice University, Houston, Texas, USA.
出版信息
Clin Transl Sci. 2009 Oct;2(5):366-73. doi: 10.1111/j.1752-8062.2009.00142.x.
Abstract
The pathophysiology of various types of thrombotic microangiopathies is coming progressively into focus. Therapeutic advances are likely to follow at a quickening pace. This discussion focuses on thrombotic thrombocytopenic purpura (TTP), the hemolytic-uremic syndrome (HUS), thrombotic microangiopathies associated with transplantation-immunosuppression or anti-angiogenesis therapy, and the preeclampsia/hemolysis-elevated liver enzymes and low platelets syndrome (HELLP).
摘要
各种类型血栓性微血管病的病理生理学逐渐成为研究焦点。治疗进展很可能会随之加快。本次讨论聚焦于血栓性血小板减少性紫癜（TTP）、溶血尿毒综合征（HUS）、与移植免疫抑制或抗血管生成治疗相关的血栓性微血管病，以及子痫前期/溶血-肝酶升高和血小板减少综合征（HELLP）。
相似文献
1
Thrombotic microangiopathies: multimers, metalloprotease, and beyond.
Clin Transl Sci. 2009 Oct;2(5):366-73. doi: 10.1111/j.1752-8062.2009.00142.x.
2
Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies.
J Thromb Haemost. 2017 Feb;15(2):312-322. doi: 10.1111/jth.13571. Epub 2017 Jan 30.
3
Thrombotic microangiopathies, thrombotic thrombocytopenic purpura, and ADAMTS-13.
Semin Thromb Hemost. 2012 Feb;38(1):47-54. doi: 10.1055/s-0031-1300951. Epub 2012 Feb 7.
4
Molecular mechanisms in thrombotic thrombocytopenic purpura.
Semin Thromb Hemost. 2004 Oct;30(5):549-57. doi: 10.1055/s-2004-835675.
5
Thrombotic microangiopathies (TTP, HUS, HELLP).
Emerg Med Clin North Am. 2014 Aug;32(3):649-71. doi: 10.1016/j.emc.2014.04.008. Epub 2014 Jun 3.
6
Recent advances in thrombotic thrombocytopenic purpura.
Hematology Am Soc Hematol Educ Program. 2004:407-23. doi: 10.1182/asheducation-2004.1.407.
7
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.
N Engl J Med. 1998 Nov 26;339(22):1578-84. doi: 10.1056/NEJM199811263392202.
8
Thrombotic thrombocytopenic purpura and other thrombotic microangiopathic hemolytic anemias: diagnosis and classification.
Autoimmun Rev. 2014 Apr-May;13(4-5):584-6. doi: 10.1016/j.autrev.2014.01.004. Epub 2014 Jan 11.
9
Thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2005 Aug;3(8):1663-75. doi: 10.1111/j.1538-7836.2005.01425.x.
10
The Differential Diagnosis and Treatment of Thrombotic Microangiopathies.
Dtsch Arztebl Int. 2018 May 11;115(19):327-334. doi: 10.3238/arztebl.2018.0327.
引用本文的文献
1
A Moderate Decrease in ADAMTS13 Activity Correlates with the Severity of STEC-HUS.
Biomolecules. 2023 Nov 20;13(11):1671. doi: 10.3390/biom13111671.
2
Immune and Hereditary Thrombotic Thrombocytopenic Purpura: Can ADAMTS13 Deficiency Alone Explain the Different Clinical Phenotypes?
J Clin Med. 2023 Apr 25;12(9):3111. doi: 10.3390/jcm12093111.
3
[Clinical course and differential diagnosis of thrombotic microangiopathy].
Med Klin Intensivmed Notfmed. 2018 May;113(4):293-298. doi: 10.1007/s00063-016-0193-5. Epub 2016 Jul 12.
4
Thrombocytopenia-Associated Multiple Organ Failure and Acute Kidney Injury.
Crit Care Clin. 2015 Oct;31(4):661-74. doi: 10.1016/j.ccc.2015.06.004. Epub 2015 Aug 7.
5
ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment.
Clin J Am Soc Nephrol. 2015 Nov 6;10(11):2002-12. doi: 10.2215/CJN.01700215. Epub 2015 Sep 4.
6
ADAMTS-13 in the Diagnosis and Management of Thrombotic Microangiopathies.
Rambam Maimonides Med J. 2014 Oct 29;5(4):e0026. doi: 10.5041/RMMJ.10160. eCollection 2014 Oct.
7
Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
Semin Thromb Hemost. 2012 Nov;38(8):845-53. doi: 10.1055/s-0032-1328894. Epub 2012 Oct 30.
本文引用的文献
1
Protein phosphatase 2B inhibition promotes the secretion of von Willebrand factor from endothelial cells.
J Thromb Haemost. 2009 Jun;7(6):1009-18. doi: 10.1111/j.1538-7836.2009.03355.x. Epub 2009 Mar 27.
2
Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project.
Blood. 2009 May 14;113(20):4834-40. doi: 10.1182/blood-2008-10-186999. Epub 2009 Mar 5.
3
Cognitive deficits after recovery from thrombotic thrombocytopenic purpura.
Transfusion. 2009 Jun;49(6):1092-101. doi: 10.1111/j.1537-2995.2009.02101.x. Epub 2009 Feb 13.
4
Ticlopidine- and clopidogrel-associated thrombotic thrombocytopenic purpura (TTP): review of clinical, laboratory, epidemiological, and pharmacovigilance findings (1989-2008).
Kidney Int Suppl. 2009 Feb(112):S20-4. doi: 10.1038/ki.2008.613.
5
The distal carboxyl-terminal domains of ADAMTS13 are required for regulation of in vivo thrombus formation.
Blood. 2009 May 21;113(21):5323-9. doi: 10.1182/blood-2008-07-169359. Epub 2008 Dec 24.
6
Thrombotic microangiopathy secondary to VEGF pathway inhibition by sunitinib.
Nephrol Dial Transplant. 2009 Feb;24(2):682-5. doi: 10.1093/ndt/gfn657. Epub 2008 Dec 2.
7
VH1-69 germline encoded antibodies directed towards ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura.
J Thromb Haemost. 2009 Mar;7(3):421-8. doi: 10.1111/j.1538-7836.2008.03250.x.
8
ADAMTS-13 cleaves long von Willebrand factor multimeric strings anchored to endothelial cells in the absence of flow, platelets or conformation-altering chemicals.
J Thromb Haemost. 2009 Jan;7(1):229-32. doi: 10.1111/j.1538-7836.2008.03209.x. Epub 2008 Oct 29.
9
Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome.
Blood. 2008 Dec 15;112(13):4948-52. doi: 10.1182/blood-2008-01-133702. Epub 2008 Sep 16.
10
VEGF inhibition and renal thrombotic microangiopathy.
N Engl J Med. 2008 Mar 13;358(11):1129-36. doi: 10.1056/NEJMoa0707330.
Zotero 插件